» Articles » PMID: 21508421

Prognosis of Invasive Intraductal Papillary Mucinous Neoplasm Depends on Histological and Precursor Epithelial Subtypes

Abstract

Objective: Invasive cancers arising from intraductal papillary mucinous neoplasm (IPMN) are recognised as a morphologically and biologically heterogeneous group of neoplasms. Less is known about the epithelial subtypes of the precursor IPMN from which these lesions arise. The authors investigate the clinicopathological characteristics and the impact on survival of both the invasive component and its background IPMN.

Design And Patients: The study cohort comprised 61 patients with invasive IPMN (study group) and 570 patients with pancreatic ductal adenocarcinoma (PDAC, control group) resected at a single institution. Multivariate analyses were performed using a stage-matched Cox proportional hazard model.

Results: The histology of invasive components of the IPMN cohort was tubular in 38 (62%), colloid in 16 (26%), and oncocytic in seven (12%). Compared with PDAC, invasive IPMNs were associated with a lower incidence of adverse pathological features and improved mortality by multivariate analysis (HR 0.58; 95% CI 0.39 to 0.86). In subtype analysis, this favourable outcome remained only for colloid and oncocytic carcinomas, while tubular adenocarcinoma was associated with worse overall survival, not significantly different from that of PDAC (HR 0.85; 95% CI 0.53 to 1.36). Colloid and oncocytic carcinomas arose only from intestinal- and oncocytic-type IPMNs, respectively, and were mostly of the main-duct type, whereas tubular adenocarcinomas primarily originated in the gastric background, which was often associated with branch-duct IPMN. Overall survival of patients with invasive adenocarcinomas arising from gastric-type IPMN was significantly worse than that of patients with non-gastric-type IPMN (p=0.016).

Conclusions: Tubular, colloid and oncocytic invasive IPMNs have varying prognosis, and arise from different epithelial subtypes. Colloid and oncocytic types have markedly improved biology, whereas the tubular type has a course that resembles PDAC. Analysis of these subtypes indicates that the background epithelium plays an equally, if not more, important role in defining the biology and prognosis of invasive IPMNs.

Citing Articles

Subtype-associated complexity and prognostic significance of the NLRP3 inflammasome landscape in pancreatic neoplasms.

Nemeth K, Mezei E, Voros J, Borka K, Pesti A, Kenessey I J Pathol Clin Res. 2025; 11(2):e70019.

PMID: 39969214 PMC: 11837281. DOI: 10.1002/2056-4538.70019.


A Review of the Indications, Outcomes, and Postoperative Management After Total and Completion Pancreatectomy for Pancreatic Cancer: More Is Not Necessarily Better.

Oppat K, Bennett F, Maithel S Surg Clin North Am. 2024; 104(5):1049-1064.

PMID: 39237163 PMC: 11889495. DOI: 10.1016/j.suc.2024.04.012.


Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer.

Habib J, Rompen I, Javed A, Grewal M, Kinny-Koster B, Andel P J Gastroenterol Hepatol. 2024; 39(11):2360-2366.

PMID: 39086101 PMC: 11618288. DOI: 10.1111/jgh.16686.


A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?.

de Jesus V, Donadio M, de Brito A, Gentilli A Ther Adv Med Oncol. 2024; 16:17588359241265213.

PMID: 39072242 PMC: 11282540. DOI: 10.1177/17588359241265213.


Precursor Epithelial Subtypes of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasms (A-IPMN): Clinicopathological Features, Recurrence and Response to Adjuvant Chemotherapy.

Lucocq J, Haugk B, Parkinson D, Darne A, Joseph N, Hawkyard J Ann Surg Oncol. 2024; 31(10):7023-7032.

PMID: 38961040 PMC: 11413116. DOI: 10.1245/s10434-024-15677-z.


References
1.
Kim G, Bae H, Park H, Kuan S, Crawley S, Ho J . Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002; 123(4):1052-60. DOI: 10.1053/gast.2002.36018. View

2.
Adsay N, Adair C, Heffess C, Klimstra D . Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol. 1996; 20(8):980-94. DOI: 10.1097/00000478-199608000-00007. View

3.
Raut C, Cleary K, Staerkel G, Abbruzzese J, Wolff R, Lee J . Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol. 2006; 13(4):582-94. DOI: 10.1245/ASO.2006.05.002. View

4.
Schnelldorfer T, Sarr M, Nagorney D, Zhang L, Smyrk T, Qin R . Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008; 143(7):639-46. DOI: 10.1001/archsurg.143.7.639. View

5.
DAngelica M, Brennan M, Suriawinata A, Klimstra D, Conlon K . Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004; 239(3):400-8. PMC: 1356240. DOI: 10.1097/01.sla.0000114132.47816.dd. View